Leda Paganini

Leda Paganini

Auto-generated profile, based on publicly available information

Leda Paganini

Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2013 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
ETEmanuela Toffolo
Emanuela Toffolo
Francesco RusconiFrancesco Rusconi
Francesco Rusconi
LPLeda Paganini
Leda Paganini
MTMarcello Tortorici
Marcello Tortorici
SPSimona Pilotto
Simona Pilotto
EBElena Battaglioli
Elena Battaglioli

14 March 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Francesco RusconiFrancesco Rusconi
Francesco Rusconi
BGBarbara Grillo
Barbara Grillo
LPLuisa Ponzoni
Luisa Ponzoni
SBSilvia Bassani
Silvia Bassani
ETEmanuela Toffolo
Emanuela Toffolo
EBElena Battaglioli
Elena Battaglioli
Behavioral changes in response to stressful stimuli can be controlled via adaptive epigenetic changes in neuronal gene expression. Here we indicate a role for the transcriptional corepressor Lysine-Specific Demethylase 1 (LSD1) and its dominant-negative splicing isoform neuroLSD1, in the modulation of emotional behavior. In mouse hippocampus, we show that LSD1 and neuroLSD1 can interact with transcription factor serum response factor (SRF) and set the chromatin state of SRF-targeted genes early growth response 1 (egr1) and c-fos. Deletion or reduction of neuroLSD1 in mutant mice translates into decreased levels of activating histone marks at egr1 and c-fos promoters, dampening their psychosocial stress-induced transcription and resulting in low anxiety-like behavior. Administration of suberoylanilide hydroxamine to neuroLSD1KO mice reactivates egr1 and c-fos transcription and restores the behavioral phenotype. These findings indicate that LSD1 is a molecular transducer of stressful stimuli as well as a stress-response modifier. Indeed, LSD1 expression itself is increased acutely at both the transcriptional and splicing levels by psychosocial stress, suggesting that LSD1 is involved in the adaptive response to stress. Significance In mammals, different forms of stress, including psychosocial stress, can affect several aspects of health, fostering mood and anxiety disorders in humans. However, a lack of knowledge about the mechanisms underlying the brain physiology of the stress response hinders the development of new therapeutic strategies. We describe the role of the epigenetic enzyme Lysine-Specific Demethylase 1 (LSD1) in the transduction pathway that translates social stress into an altered transcriptional physiology of plasticity genes in hippocampus. In particular, we show that in the brain LSD1 is finely tuned by a mammal-restricted splicing-based mechanism, and its demethylase activity consistently affects anxiety-like behavior in mice. This work addresses a fundamental mechanism, explaining a brain-related phenotype as a result of genome–environment interactions mediated by the epigenome.

15 April 2014 in Cerebral Cortex
Verified
Journal Article
Open access
PDF file
Francesco RusconiFrancesco Rusconi
Francesco Rusconi
LPLeda Paganini
Leda Paganini
DBDaniela Braida
Daniela Braida
LPLuisa Ponzoni
Luisa Ponzoni
ETEmanuela Toffolo
Emanuela Toffolo
EBElena Battaglioli
Elena Battaglioli
Alternative splicing in the brain is dynamic and instrumental to adaptive changes in response to stimuli. Lysine-specific demethylase 1 (LSD1/KDM1A) is a ubiquitously expressed histone H3Lys4 demethylase that acts as a transcriptional co-repressor in complex with its molecular partners CoREST and HDAC1/2. In mammalian brain, alternative splicing of LSD1 mini-exon E8a gives rise to neuroLSD1, a neurospecific isoform that, upon phosphorylation, acts as a dominant-negative causing disassembly of the co-repressor complex and de-repression of target genes. Here we show that the LSD1/neuroLSD1 ratio changes in response to neuronal activation and such effect is mediated by neurospecific splicing factors NOVA1 and nSR100/SRRM4 together with a novel cis-silencer. Indeed, we found that, in response to epileptogenic stimuli, downregulation of NOVA1 reduces exon E8a splicing and expression of neuroLSD1. Using behavioral and EEG analyses we observed that neuroLSD1-specific null mice are hypoexcitable and display decreased seizure susceptibility. Conversely, in a mouse model of Rett syndrome characterized by hyperexcitability, we measured higher levels of NOVA1 protein and upregulation of neuroLSD1. In conclusion, we propose that, in the brain, correct ratio between LSD1 and neuroLSD1 contributes to excitability and, when altered, could represent a pathogenic event associated with neurological disorders involving altered E/I.

14 October 2014 in Human Reproduction
Verified
Journal Article
Open access
PDF file
APAlessandra Pansa
Alessandra Pansa
Silvia SirchiaSilvia Sirchia
Silvia Sirchia
SMSara Melis
Sara Melis
DGDaniela Giacchetta
Daniela Giacchetta
MCMirco Castiglioni
Mirco Castiglioni
STSilvia Tabano
Silvia Tabano
Is the presence of ESX1 mRNA in seminal fluid (SF) an indicator of residual spermatogenesis in men with non-obstructive azoospermic (NOA)? ESX1 mRNA in SF is a suitable molecular marker for predicting the presence of residual spermatogenesis in testis. ESX1 is an X-linked homeobox gene whose expression in testis is restricted to germ cells. We previously reported, in the testicular biopsies from azoospermic men, a positive correlation between the presence of ESX1 mRNA and residual spermatogenesis. We investigated ESX1 mRNA expression in 70 testicular fragments (TF) and 56 (SF) of 70 NOA men. As controls, we analyzed 8 TF from men with obstructive azoospermic (OA) and 9 SF from normozoospermic men. For all patients we considered the histological classification of testis biopsies and the recovery of spermatozoa by surgical procedures. Relative ESX1 mRNA expression was evaluated by quantitative RT–PCR using the ΔΔCt method. The results were compared with the recovery of spermatozoa at surgery. In TF from NOA patients we found that: (i) ESX1 mRNA level was significantly decreased as the severity of spermatogenic defects increased (P < 0.0001, one-way analysis of variance); (ii) the presence of ESX1 mRNA can predict the success of sperm retrieval (sensitivity: 80%). In SF from NOA patients we found that: (i) ESX1 mRNA was present in 78.5% of NOA men; (ii) the presence of ESX1 mRNA could predict the success of sperm retrieval (sensitivity: 84%). Spermatozoa were recovered at surgery in 5 out of 12 patients whose SF was negative for ESX1 mRNA expression. We think that discrepancies between molecular and clinical results could be reduced by analyzing more than one ejaculate from each man. The data confirm that the ESX1 transcript in the semen of men with NOA is a suitable molecular marker for predicting the presence of residual foci of spermatogenesis in the testis. The implication of these results is that some patients ‘with azoospermia’, although having a severe impairment of spermatogenesis, could still maintain residual foci of spermatogenesis in limited areas of the testes, not always recovered by surgery. This work was supported by the Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico: Ricerca Corrente [grant number RC2014/519-02] to M.M. and from ASM onlus 2010–2011 to M.M. The authors declare that they have no conflict of interest.

5 June 2015 in Epigenetics
Verified
Journal Article
Open access
LPLeda Paganini
Leda Paganini
NCNicole Carlessi
Nicole Carlessi
LFLaura Fontana
Laura Fontana
RSRosamaria Silipigni
Rosamaria Silipigni
SMSilvia Motta
Silvia Motta
STSilvia Tabano
Silvia Tabano
Beckwith–Wiedemann syndrome (BWS) is an imprinting disorder that can be prenatally suspected or diagnosed based on established clinical guidelines. Molecular confirmation is commonly performed on amniocytes. The possibility to use fresh (CVF) and cultured (CVC) chorionic villi has never been investigated. To verify whether CVF and CVC are reliable sources of DNA to study fetal methylation, we used pyrosequencing to test the methylation level of a number of differentially methylated regions (DMRs) at several imprinted loci (ICR1, ICR2, H19, PWS/AS-ICR, GNASXL, GNAS1A, ZAC/PLAGL1, and MEST) and at non-imprinted MGMT and RASSF1A promoters. We analyzed these regions in 19 healthy pregnancies and highlighted stable methylation levels between CVF and CVC at ICR1, ICR2, GNASXL, PWS/AS-ICR, and MEST. Conversely, the methylation levels at H19 promoter, GNAS1A and ZAC/PLAGL1 were different in CVC compared to fresh CV. We also investigated ICR1 and ICR2 methylation level of CVF/CVC of 2 BWS-suspected fetuses (P1 and P2). P1 showed ICR2 hypomethylation, P2 showed normal methylation at both ICR1 and ICR2. Our findings, although limited to one case of BWS fetus with an imprinting defect, can suggest that ICR1 and ICR2, but not H19, could be reliable targets for prenatal BWS diagnosis by methylation test in CVF and CVC. In addition, PWS/AS-ICR, GNASXL, and MEST, but not GNAS1A and ZAC/PLAGL1, are steadily hemimethylated in CV from healthy pregnancies, independently from culture. Thus, prenatal investigation of genomic imprinting in CV needs to be validated in a locus-specific manner.

24 November 2018 in Clinical Genetics
Verified
Journal Article
Open access
PDF file
LPLeda Paganini
Leda Paganini
LHLoubna Abdel Hadi
Loubna Abdel Hadi
Chetta MassimilianoChetta Massimiliano
Chetta Massimiliano
DRDavide Rovina
Davide Rovina
LFLaura Fontana
Laura Fontana
MMMonica Miozzo
Monica Miozzo
X‐linked intellectual disability (XLID) refers to a clinically and genetically heterogeneous neurodevelopmental disorder, in which males are more heavily affected than females. Among the syndromic forms of XLID, identified by additional clinical signs as part of the disease spectrum, the association between XLID and severe myopia has been poorly characterized. We used whole exome sequencing (WES) to study two Italian male twins presenting impaired intellectual function and adaptive behavior, in association with severe myopia and mild facial dysmorphisms. WES analysis detected the novel, maternally inherited, mutation c.916G > C (G306R) in the X‐linked heparan sulfate 6‐O‐sulfotransferase 2 (HS6ST2) gene. HS6ST2 transfers sulfate from adenosine 3′‐phosphate, 5′‐phosphosulfate to the sixth position of the N‐sulphoglucosamine residue in heparan sulfate (HS) proteoglycans. Low HS sulfation levels are associated with defective optic disc and stalk morphogenesis during mammalian visual system development. The c.916G>C variant affects the HS6ST2 substrate binding site, and its effect was considered “deleterious” by in‐silico tools. An in‐vitro enzymatic assay showed that the HS6ST2 mutant isoform had significantly reduced sulphotransferase activity. Taken together, the results suggest that mutant HS6ST2 is possibly involved in the development of myopia and cognitive impairment, characteristics of the probands reported here.